Lv6
2670 积分 2023-07-21 加入
Pembrolizumab versus Ipilimumab in Advanced Melanoma
1天前
待确认
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
1天前
待确认
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
1天前
待确认
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
1天前
待确认
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
1天前
待确认
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
1天前
待确认
Pembrolizumab for Early Triple-Negative Breast Cancer
1天前
待确认
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
1天前
待确认
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
1天前
待确认
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
1天前
待确认
皖公网安备34019202002308
